Hu et al. demonstrated in preclinical models that MAPK reactivation induced by treatment with BLU-667 led to the upregulation of Aurora A/B kinases, which resulted in tumor regression when inhibited in combination with RET inhibition [35]. Here, RET is linked to neoplasm.